445
Participants
Start Date
December 17, 2008
Primary Completion Date
May 14, 2012
Study Completion Date
May 14, 2012
Riociguat (Adempas, BAY63-2521)
BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
Riociguat (Adempas, BAY63-2521)
BAY63-2521: 1.5mg tid orally for 12 weeks
Placebo
Matching Placebo tid orally for 12 weeks
Taipei
Bruxelles - Brussel
Vienna
Darlinghurst
New Lambton Heights
Leuven
Prahran
Linz
Herston
Auchenflower
Innsbruck
Royal Hobart Hospital, Hobart
Christchurch
Zurich
Aarhus N
New York
Turin
Bangkok
Taipei
Prague
Mexico City
Greifswald
Milan
Besançon
Pavia
Hanover
Pessac
Montpellier
Istanbul
Trieste
Giessen
Querétaro
Grenoble
Louisville
Seville
Columbus
Cleveland
Guadalajara
Guadalajara
Fairfield
Cincinnati
Chiang Mai
Cologne
Lille
Monterrey
Homburg
Omaha
Heidelberg
Dallas
Rouen
Houston
El Paso
Culiacán
Aurora
München
Tucson
Los Angeles
La Jolla
Sacramento
Beijing
Beijing
Singapore
Moscow
Singapore
Saint Petersburg
Shanghai
Shanghai
Guangzhou
Kaohsiung City
Petah Tikva
Boston
Boston
Providence
Capital Federal
Ankara
Porto Alegre
São Paulo
São Paulo
Rio de Janeiro
Calgary
Toronto
Montreal
Brest
Nice
Dresden
Leipzig
Chaïdári
Rome
Nagoya
Yoshida
Kobe
Toride
Tsukuba
Kanazawa
Sagamihara
Sendai
Tomigusuku
Bunkyo-ku
Mitaka
Ōta-ku
Shinjuku-ku
Hiroshima
Okayama
Otwock
Coimbra
Lisbon
Lisbon
Porto
Seoul
Seoul
Seoul
Seoul
Barcelona
Barcelona
Linköping
Lund
Umeå
Izmir
Cambridge
Clydebank
London
London
Lead Sponsor
Bayer
INDUSTRY